Snowball logo
logo
OASM_logo

Oasmia Pharmaceutical AB

OASMY • PINK
$0.1974+$0.1774  (887%)
Estimate
EPS
-0.02
Beta
0.823
About the company
Ticker
OASMY
ISIN
US67421W1099
Country
Sweden
Sector (GICS)
Healthcare
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.

Frequently asked questions

What sector does Oasmia Pharmaceutical AB (OASMY) operate in?

Oasmia Pharmaceutical AB belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is Oasmia Pharmaceutical AB (OASMY) current stock price?

As of the latest data, Oasmia Pharmaceutical AB stock price is $0.20, with a previous close of $0.02. Oasmia Pharmaceutical AB gained $0.18 in the last trading session, representing a 887% increase.

What is Oasmia Pharmaceutical AB (OASMY) current market capitalization?

Oasmia Pharmaceutical AB market cap is approximately 72.85 million.

What is Oasmia Pharmaceutical AB (OASMY) Earnings Per Share (EPS)?

The trailing EPS is -$0.02.

Does Oasmia Pharmaceutical AB (OASMY) pay dividends?

No. Oasmia Pharmaceutical AB does not pay a dividend.

What is Oasmia Pharmaceutical AB (OASMY) beta (volatility) score?

Oasmia Pharmaceutical AB has a beta of 0.823, meaning its volatility is roughly in line with the market.